Redx Pharma Plc CEO Neil Murray talks about the progress the drug discovery firm has made since the IPO in March.
“I would like to say we are setting the bar, rather than playing catch-up…we are very much pushing the boundaries,” he said. Talking about the group’s MRSA programme in particular “We have produced the first new class of drugs in a generation – there hasn’t been a new class of antibiotics in about twenty years. That is a huge step forward in the fight against resistant infection,” he said. See ProactiveInvestors.co.uk